FR20C1036I1 - PERIVASCULAR MESENCHYMAL PRECURSOR CELLS - Google Patents

PERIVASCULAR MESENCHYMAL PRECURSOR CELLS

Info

Publication number
FR20C1036I1
FR20C1036I1 FR20C1036C FR20C1036I1 FR 20C1036 I1 FR20C1036 I1 FR 20C1036I1 FR 20C1036 C FR20C1036 C FR 20C1036C FR 20C1036 I1 FR20C1036 I1 FR 20C1036I1
Authority
FR
France
Prior art keywords
precursor cells
mesenchymal precursor
perivascular mesenchymal
perivascular
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast Inc
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31500707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR20C1036I1 publication Critical patent/FR20C1036I1/en
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Application granted granted Critical
Publication of FR20C1036I2 publication Critical patent/FR20C1036I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1392—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR20C1036C 2003-03-28 2020-08-06 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS Active FR20C1036I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003901668A AU2003901668A0 (en) 2003-03-28 2003-03-28 Non-haemopoietic precursor cells
PCT/AU2004/000416 WO2004085630A1 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cells
EP04723935A EP1613741A4 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cells

Publications (2)

Publication Number Publication Date
FR20C1036I1 true FR20C1036I1 (en) 2020-02-10
FR20C1036I2 FR20C1036I2 (en) 2022-11-18

Family

ID=31500707

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1036C Active FR20C1036I2 (en) 2003-03-28 2020-08-06 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS

Country Status (14)

Country Link
US (6) US9169466B2 (en)
EP (4) EP2380971B1 (en)
JP (10) JP2006521096A (en)
CN (4) CN103224907B (en)
AU (7) AU2003901668A0 (en)
CA (4) CA2872395A1 (en)
DK (1) DK1613335T3 (en)
ES (3) ES2689483T3 (en)
FR (1) FR20C1036I2 (en)
NL (1) NL301059I2 (en)
PL (1) PL1613335T3 (en)
PT (1) PT1613335E (en)
SI (1) SI1613335T1 (en)
WO (2) WO2004085630A1 (en)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
EP2277992A3 (en) * 2003-02-11 2011-03-02 John E. Davies Progenitor cells from Wharton's jelly of human umbilical cord
KR101536613B1 (en) 2004-09-24 2015-07-14 메소블라스트, 아이엔씨. Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
ES2645012T3 (en) 2004-09-24 2017-12-01 Mesoblast, Inc. Method to enhance the proliferation and / or survival of mesenchymal precursor cells (MPC)
EP1846548B1 (en) 2005-02-11 2010-09-08 Agency for Science, Technology and Research Methods of proliferating stem cells
US8287853B2 (en) 2005-02-11 2012-10-16 Agency For Science, Technology And Research Methods of culturing mesenchymal stem cells
AU2006235211B2 (en) * 2005-04-12 2010-10-14 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
EP1909581A4 (en) * 2005-07-29 2008-12-31 Univ Virginia STEM CELLS OF ADIPOSE TISSUES, PERIVASCULAR CELLS AND PERICYTES
EP1780265A1 (en) * 2005-10-25 2007-05-02 Stiftung CAESAR Differentiation of stem cells into chondrocytes
CA2634820C (en) 2005-12-22 2021-05-25 Jane Ennis Viable cells from frozen umbilical cord tissue
WO2007128115A1 (en) * 2006-05-05 2007-11-15 Univ Toronto Immune privileged and modulatory progenitor cells
DK2046349T3 (en) * 2006-07-12 2015-12-21 Mesoblast Inc TREATMENT OF EXCESSIVE NEOVASCULARIZATION
FR2909559B1 (en) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang CELLULAR PREPARATIONS FOR USE AS AGENT STIMULATING REVASCULARIZATION
WO2008077094A2 (en) * 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
US20100158874A1 (en) * 2007-02-26 2010-06-24 Mount Sinai Hospital Compositions and Methods for Treating Peripheral Vascular Diseases
KR20100066494A (en) 2007-08-06 2010-06-17 안지오블라스트 시스템스 인코퍼레이티드 Methods of generating, repairing and/or maintaining connective tissue in vivo
KR20100137006A (en) * 2008-04-21 2010-12-29 티슈 리제너레이션 쎄라퓨틱스, 인코포레이티드 Genetically modified human umbilical vessel cells for the prevention or treatment of biological or chemical substances
ES2692879T3 (en) * 2008-06-25 2018-12-05 Mesoblast, Inc. Repair and / or reconstitution of invertebral discs
EP2294184A4 (en) * 2008-06-30 2013-03-06 Mesoblast Inc Treatment of eye diseases and excessive neovascularization using a combined therapy
WO2010011185A1 (en) * 2008-07-21 2010-01-28 Agency For Science, Technology And Research Stem cells obtained through in vitro culture with heparan sulfate
KR20110050521A (en) 2008-08-20 2011-05-13 안트로제네시스 코포레이션 Improved Cell Compositions and Methods of Making the Same
MX2008014536A (en) * 2008-11-13 2009-01-16 Internac Para La Terapia Celul Cellular regenerator compound.
WO2010057260A1 (en) 2008-11-20 2010-05-27 Angioblast Systems, Inc. Method for treating or preventing a pancreatic dysfunction
EP2408904B1 (en) * 2009-03-20 2017-10-18 Mesoblast, Inc. Production of reprogrammed pluripotent cells
WO2011022071A2 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of California Cardiac compositions
JP5714019B2 (en) * 2009-10-21 2015-05-07 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ Biomarker for diagnosis, prognosis and / or prognosis of acute heart failure and use thereof
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
WO2012000064A1 (en) 2010-07-02 2012-01-05 Angioblast Systems, Inc. Method of treating graft versus host disease
US9301976B2 (en) * 2010-08-19 2016-04-05 The Regents Of The University Of California Compositions comprising perivascular stem cells and nell-1 protein
CN101985052B (en) * 2010-08-31 2013-11-06 中国人民解放军第二军医大学 Skin substitute for automatically capturing endothelial progenitor cells and promoting vascularization and construction method thereof
WO2012040408A2 (en) * 2010-09-23 2012-03-29 Children's Medical Center Corporation Engineered vascular adipose tissue
EP2624845A4 (en) 2010-10-08 2015-09-09 Mesoblast Internat S Rl REINFORCED MSC PREPARATIONS
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
AU2012255621A1 (en) * 2011-05-19 2013-05-02 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
KR102002090B1 (en) * 2011-06-03 2019-07-19 메소블라스트, 아이엔씨. Methods of treating or preventing neurological diseases
JP6265890B2 (en) * 2011-06-03 2018-01-24 メゾブラスト，インコーポレーテッド How to treat the effects of cerebral infarction
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
WO2013003899A1 (en) 2011-07-04 2013-01-10 Mesoblast, Inc Methods of treating or preventing rheumatic disease
CA2840307C (en) 2011-07-06 2021-10-19 Cell Therapy Limited Progenitor cells of mesodermal lineage
EP2734618B1 (en) * 2011-07-20 2017-06-14 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Pluripotent tendon and ligament perivascular cells
JP2014529406A (en) * 2011-08-29 2014-11-13 セーフガードセル テクノロジー インク． Isolation and therapeutic use of perivascular medicinal cells
JP5831059B2 (en) * 2011-09-07 2015-12-09 ソニー株式会社 Optical measuring apparatus, flow cytometer, and optical measuring method
US9177336B2 (en) * 2011-09-08 2015-11-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatuses and methods for recommending a path through an information space
CA2847575C (en) * 2011-09-09 2021-10-19 Mesoblast, Inc. Method for increasing osteoblastic function
CN102539736B (en) * 2011-12-16 2015-04-29 北京汉氏联合生物技术有限公司 CD106-positive cells, and identification and preparation method and application thereof
JP6901823B2 (en) * 2012-08-01 2021-07-14 ユナイテッド セラピューティクス コーポレイション Treatment of pulmonary arterial hypertension with mesenchymal stem cells
EP2879684B1 (en) 2012-08-01 2019-01-30 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
JP6313327B2 (en) 2012-12-12 2018-04-18 メソブラスト、インコーポレイテッド Method for treating or preventing respiratory diseases
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
CA2897805C (en) * 2013-01-09 2023-03-21 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
EP3027235A1 (en) 2013-07-30 2016-06-08 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
EP3068866B1 (en) 2013-11-16 2018-04-25 Terumo BCT, Inc. Expanding cells in a bioreactor
KR20160096640A (en) * 2013-12-13 2016-08-16 메조블라스트 인터내셔널 에스에이알엘 Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
CA2944262C (en) * 2014-04-07 2023-08-01 Mesoblast International Sarl Improved stem cell composition
CA2944703C (en) 2014-04-11 2023-09-19 The Administrators Of The Tulane Educational Fund Cell-surface marker of early msc aging
KR102704978B1 (en) 2014-06-10 2024-09-09 메조블라스트 인터내셔널 에스에이알엘 Treatment of immune disorders
EP3168297B1 (en) * 2014-07-11 2020-09-16 Metcela Inc. Cardiac cell culture material
JP6830059B2 (en) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド Scheduled cell feeding
JP7315301B2 (en) 2014-12-23 2023-07-26 メゾブラスト・インターナショナル・エスアーエールエル Prevention of progressive heart failure
BR112017012911B1 (en) 2014-12-23 2021-10-05 Mesoblast International Sàrl METHOD FOR TREATMENT OF HEART FAILURE
KR102635212B1 (en) 2015-03-04 2024-02-13 메조블라스트 인터내셔널 에스에이알엘 Cell culture method for mesenchymal stem cells
WO2016177805A1 (en) 2015-05-05 2016-11-10 Mesoblast International Sàrl Potency assay
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN106119189B (en) * 2016-07-11 2020-04-10 山东亚大药业有限公司 Separation and purification method and kit for fetal nucleated red blood cells
ES2927406T3 (en) 2016-10-24 2022-11-04 United Therapeutics Corp Potentiation of the immunomodulatory properties of MSCs by treprostinil
EP3543331A4 (en) 2016-11-15 2020-07-01 Kaneka Corporation CELL POPULATION WITH MESENCHYMAL STEM CELLS FROM FETAL ATTACHMENTS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL COMPOSITION
ES2885080T3 (en) * 2017-02-24 2021-12-13 Metcela Inc Injectable composition comprising fibroblasts for use in the treatment of heart disease
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
WO2018202853A1 (en) 2017-05-04 2018-11-08 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
BR112020010079A2 (en) 2017-11-22 2020-11-03 Mesoblast International Sàrl cell compositions and treatment methods i
US12186345B2 (en) 2017-12-28 2025-01-07 Kaneka Corporation Cell population including adhesive stem cells, production method therefor and pharmaceutical composition
SG11202103901YA (en) 2018-10-31 2021-05-28 Mesoblast Int Sarl Expansion of hematopoietic stem cells
CN109321522A (en) * 2018-11-20 2019-02-12 潍坊市康华生物技术有限公司 A method of preparing dental pulp stem cell
WO2020141473A1 (en) 2019-01-02 2020-07-09 Mesoblast International Sárl Method for treating lower back pain
EP3906036A1 (en) 2019-01-03 2021-11-10 Mesoblast International Sàrl Method for improving visual acuity
WO2020157660A1 (en) 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
SG11202112449SA (en) 2019-05-23 2021-12-30 Mesoblast Int Sarl Functional recovery from cerebral infarction
CN113993527B (en) 2019-06-14 2025-07-01 株式会社钟化 Cell population containing mesenchymal cells, pharmaceutical composition containing the same, and method for producing the same
JP2022543445A (en) 2019-08-05 2022-10-12 メゾブラスト・インターナショナル・エスアーエールエル Cell compositions and methods of treatment containing viral vectors
KR20230046298A (en) 2020-08-10 2023-04-05 메조블라스트 인터내셔널 에스에이알엘 Cell compositions and treatment methods
JP7705950B2 (en) 2021-03-23 2025-07-10 テルモ ビーシーティー、インコーポレーテッド How to grow cells
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
EP4536253A1 (en) 2022-06-08 2025-04-16 Mesoblast International Sàrl Mesenchymal progenitor cells for enhancing partial reprogramming of target cells
CN115184246B (en) * 2022-09-14 2023-07-04 天津昂赛细胞基因工程有限公司 Method for evaluating biological efficacy of mesenchymal stem cells by using CD155
AU2023389700A1 (en) 2022-12-09 2025-07-10 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation
KR20250134601A (en) 2022-12-09 2025-09-11 메조블라스트 인터내셔널 에스에이알엘 Conditioning media and their uses
CN120603931A (en) 2022-12-09 2025-09-05 迈索布拉斯特国际有限公司 Pre-permissive compositions and cell culture methods
WO2025062365A1 (en) 2023-09-22 2025-03-27 Mesoblast International Sárl Mesenchymal lineage precursor or stem cells (mlpscs) for use in methods of treating congenital heart disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
IL107642A0 (en) 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5405722A (en) * 1993-12-22 1995-04-11 Rca Thomson Licensing Corp. Method for combined baking-out and sealing of an electrophotographically processed screen assembly for a cathode-ray tube
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1997018298A1 (en) 1995-11-14 1997-05-22 Regents Of The University Of Minnesota Ex vivo culture of stem cells
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6261549B1 (en) 1997-07-03 2001-07-17 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
JP4562816B2 (en) * 1997-07-14 2010-10-13 オシリス セラピューティクス，インコーポレイテッド Use and composition of mesenchymal stem cells for myocardial regeneration
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
ATE368731T1 (en) 1998-05-29 2007-08-15 Osiris Therapeutics Inc HUMAN CD45+ AND/OR FIBROBLASTS+ MESENCHYMAL STEM CELLS
JP2002521493A (en) * 1998-07-31 2002-07-16 ジェンザイム コーポレーション Improvement of cardiac function by mesenchymal stem cell transplantation
JP2002537849A (en) * 1999-03-10 2002-11-12 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション Fat-derived stem cells and lattice
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU6298400A (en) 1999-07-26 2001-02-13 Chemetall Plc Metal surface treatment
WO2002064748A2 (en) 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
DK1226233T3 (en) 1999-08-05 2011-10-03 Abt Holding Co Multipotent adult stem cells and methods for isolation thereof
CA2346362C (en) 2000-05-26 2010-06-15 Stemcell Technologies Inc. Novel antibody compositions for preparing enriched mesenchymal progenitor preparations
ES2423898T3 (en) * 2000-07-21 2013-09-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dental pulp cytoblasts of adult humans in vitro and in vivo
FR2827868A1 (en) * 2001-07-30 2003-01-31 Bp Chem Int Ltd Continuous production of styrene polymers, e.g. high-impact polystyrene, involves bulk polymerisation followed by two-stage devolatilisation of the melt in a special system to remove unreacted monomer and oligomers
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
JP2003052365A (en) * 2001-08-20 2003-02-25 Japan Science & Technology Corp Isolation of mesenchymal stem cells from mammals and methods for using the same
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP4061487B2 (en) * 2002-11-21 2008-03-19 始 大串 Transplant material for angiogenesis and method for producing the same
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
AU2003231015B2 (en) * 2003-04-19 2009-10-08 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Postnatal stem cells and uses thereof
KR101536613B1 (en) 2004-09-24 2015-07-14 메소블라스트, 아이엔씨. Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
ES2645012T3 (en) 2004-09-24 2017-12-01 Mesoblast, Inc. Method to enhance the proliferation and / or survival of mesenchymal precursor cells (MPC)
GB0812683D0 (en) * 2008-07-11 2008-08-20 Chalabi Rifat A Multi-heat zone gasifier
US7942266B2 (en) * 2009-04-01 2011-05-17 Lincoln Global, Inc. Electrode packaging to reduce handling damage

Also Published As

Publication number Publication date
CN103224907A (en) 2013-07-31
CA2816489C (en) 2022-08-23
EP2380971B1 (en) 2020-02-12
AU2003901668A0 (en) 2003-05-01
EP1613335A4 (en) 2007-07-04
JP6096232B2 (en) 2017-03-15
NL301059I1 (en) 2020-08-12
SI1613335T1 (en) 2014-08-29
EP1613741A4 (en) 2007-07-04
NL301059I2 (en) 2021-09-16
US10421946B2 (en) 2019-09-24
CA2520390C (en) 2015-03-24
EP1613741A1 (en) 2006-01-11
CN1822846B (en) 2013-03-20
US20160317581A1 (en) 2016-11-03
EP2380969A3 (en) 2011-11-09
DK1613335T3 (en) 2014-05-19
CA2520273A1 (en) 2004-10-07
WO2004085630A1 (en) 2004-10-07
AU2009227881A1 (en) 2009-11-12
JP2013256515A (en) 2013-12-26
US20150368614A1 (en) 2015-12-24
WO2004084921A1 (en) 2004-10-07
EP2380971A2 (en) 2011-10-26
AU2009227897A1 (en) 2009-11-12
AU2004224830A1 (en) 2004-10-07
ES2465226T3 (en) 2014-06-05
JP6096082B2 (en) 2017-03-15
CA2816489A1 (en) 2004-10-07
CA2520273C (en) 2015-06-02
AU2006203628A1 (en) 2006-09-07
AU2004223798A1 (en) 2004-10-07
JP6043469B2 (en) 2016-12-14
EP2380969A2 (en) 2011-10-26
CN103224907B (en) 2015-05-06
EP2380969B1 (en) 2018-07-04
US7947266B2 (en) 2011-05-24
JP2015110659A (en) 2015-06-18
CN1809632A (en) 2006-07-26
CN1822846A (en) 2006-08-23
JP2006521121A (en) 2006-09-21
AU2006203627A1 (en) 2006-09-07
US20060286077A1 (en) 2006-12-21
CA2520390A1 (en) 2004-10-07
PT1613335E (en) 2014-05-19
EP1613335B1 (en) 2014-02-12
US9175267B2 (en) 2015-11-03
AU2004223798B2 (en) 2006-06-15
JP2006521096A (en) 2006-09-21
US20170204373A9 (en) 2017-07-20
JP2011072315A (en) 2011-04-14
JP2017148076A (en) 2017-08-31
AU2009227881B2 (en) 2011-08-25
ES2784378T3 (en) 2020-09-24
JP6188435B2 (en) 2017-08-30
US20120082649A1 (en) 2012-04-05
FR20C1036I2 (en) 2022-11-18
JP5721302B2 (en) 2015-05-20
PL1613335T3 (en) 2014-09-30
ES2689483T3 (en) 2018-11-14
JP2019006814A (en) 2019-01-17
JP2017014285A (en) 2017-01-19
AU2004224830B2 (en) 2006-06-29
US20060193840A1 (en) 2006-08-31
US20070065938A1 (en) 2007-03-22
US9169466B2 (en) 2015-10-27
JP2015156874A (en) 2015-09-03
EP2380971A3 (en) 2012-01-25
JP2013208130A (en) 2013-10-10
EP1613335A1 (en) 2006-01-11
CA2872395A1 (en) 2004-10-07
AU2009227897B2 (en) 2011-09-15
CN103202857A (en) 2013-07-17
JP6257559B2 (en) 2018-01-10
CN1809632B (en) 2013-06-05

Similar Documents

Publication Publication Date Title
FR20C1036I2 (en) PERIVASCULAR MESENCHYMAL PRECURSOR CELLS
EP1644135A4 (en) IMPROVED SOLAR CELLS
DE60336590D1 (en) FUEL CELL
EP1670385A4 (en) NEW POROUS BIOMATERIALS
EP1809740A4 (en) CARDIAC STEM CELLS
EP1856248A4 (en) HOMOGENEOUS NEURAL PRECURSOR CELLS
DE602004008220D1 (en) FUEL CELL
DE602005003581D1 (en) ELECTROLYSIS CELL
EP1541669A4 (en) MICROCHAMBER CELL CULTURE
DE502005004462D1 (en) power float
EP2095405A4 (en) SOLAR CELLS
DE602004023588D1 (en) FUEL CELL
DE602005000791D1 (en) interconnector
IS2736B (en) Makrólíðsamrunaefnasambönd with @ @ @ anti-inflammatory activity
DE602005025931D1 (en) FUEL CELL
DE602004025608D1 (en) FUEL CELL
EP1640453A4 (en) DIGITAL CELL
DE602005023645D1 (en) fuel cell
DE602004030501D1 (en) fuel cell
DE602005026944D1 (en) FUEL CELL
DE602004028858D1 (en) fuel cell
DE502004008433D1 (en) CELL
EP1685237A4 (en) NEW MULTIPOTENT STEM CELLS
EP1563058A4 (en) HEMANGIOBLAST PROGENITOR CELLS
DE602004012181D1 (en) Thermo-electrochemical conversion arrangement